Another Death, More Cases of Vision Loss Linked to Tainted Eye Drops

MONDAY, May 22, 2023 (HealthDay News) -- Cases of vision loss and deaths are mounting in an investigation into eye drops contaminated with a rare strain of the drug-resistant bacteria, Pseudomonas aeruginosa.
In all, four people have died, with one new death now being reported by the U.S. Centers for Disease Control and Prevention. Meanwhile, a total of 14 people have experienced vision loss, with six new cases reported last week. Infections have now been reported in 81 people living in 18 states. Four cases have involved people who have had to have their eyeballs surgically removed.
The cases involve 10 brands of eye drops, most commonly EzriCare Artificial Tears. Global Pharma Healthcare's Artificial Tears Lubricant Eye Drops were first recalled in February. The drops were distributed by EzriCare and Delsam Pharma.
Among the newly identified patients, many had either remembered using the eyedrops or lived in long-term care facilities in which others were infected with the bacteria. The bacteria can spread to those who have not used the drops, the CDC noted.
Signs of infection can include yellow, green, or clear discharge from the eye. They can also include eye pain or discomfort, redness of the eye or eyelid, foreign body sensation, light sensitivity, and blurry vision.
The U.S. Food and Drug Administration inspected the Global Pharma facility for 11 days in mid-February. In a report that was released afterward, the agency said that the plant's manufacturing process "lacked assurance of product sterility" for batches made between December 2020 and April 2022.
Related Posts
Poll: Most Americans Over 50 Suffer Some Type of Joint Pain
TUESDAY, Sept. 13, 2022 (HealthDay News) -- Aching joints are common for people...
Compliance With CMS Price Transparency Rule Improved With Penalty Increases
FRIDAY, June 30, 2023 (HealthDay News) -- Compliance with the U.S. Centers for...
Efgartigimod Efficacious, Safe for Primary Immune Thrombocytopenia
FRIDAY, Oct. 6, 2023 (HealthDay News) -- The first-in-class novel human...
Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer
FRIDAY, Aug. 19, 2022 (HealthDay News) -- Gemcitabine plus docetaxel (Gem/Doce)...